Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +22.8%
S&P 500 total return (same window) +37.0%
Excess return -14.2%

Annualized: +17.8% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

04
Consumer Discretionary 54.9%
Healthcare 45.1%

Full portfolio 2 positions

05
Type Streak 8Q trend
CAVA CAVA Group, Inc. Common Stock $510,747,055 54.85% 6,507,990 $-258,449,336 Down ×1
LXRX Lexicon Pharmaceuticals, Inc. - Common Stock $420,374,549 45.15% 175,156,062 $178,988,999 Up ×2

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
CAVA Trimmed -3.0M -$258.4M
LXRX Bought more +20.4M +$179.0M